IGSF8 | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | IGSF8 , CD316, CD81P3, EWI-2, EWI2, KCT-4, LIR-D1, PGRL, immunoglobulin superfamily member 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 606644; MGI: 2154090; HomoloGene: 14163; GeneCards: IGSF8; OMA:IGSF8 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunoglobulin superfamily member 8 is a protein that in humans is encoded by the IGSF8 gene. [5] [6] [7] IGSF8 has also been designated as CD316 (cluster of differentiation 316). IGSF8 is an innate immune checkpoint that inhibits the cytotoxic activity of natural killer (NK) cells. [8] IGSF8 acts by binding to the Killer Ig-like Receptor KIR3DL2 (or, in mice, the analogous Klra9 receptor). [8] IGSF8 is frequently overexpressed relative to normal tissues in many cancers, included melanoma, urothelial carcinoma, and breast cancer, [8] and has been proposed as a potential therapeutic target in gliomas. [9] In normal tissues, IGSF8 is highly expressed in the brain, where it may contribute to the immune privilege of the central nervous system. [8]
In gliomas, IGSF8 is strongly correlated with tumor grade and is a potential prognostic marker. [9] IGSF8 is enriched on ovarian cancer-derived extracellular vesicles and is a potential biomarker for the early detection of high grade serous ovarian cancer. [10]